

Docket No.: INT-001B
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Daniel Wermeling

Application No.: 10/647,789

Confirmation No.: 2016

Filed: August 25, 2003

Art Unit: 1614

For: INTRANASAL OPIOID COMPOSITIONS

Examiner: T. E. Betton

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "Reference Cites" on any patent to issue therefrom.

The information Disclosure Statement is filed after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent publications. Applicant submits copies of foreign patent documents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any

patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

Applicant has identified in the table below certain co-pending U.S. patent applications for the Office's consideration during the examination of the instant application.

Examiner Initials	Our Docket No.	Serial No.	Title	Filing Date	Status
	INT-001(B)	10/647,789	Intranasal Opioid Components	25 Aug 2003	Pending Publication No. US-2004-0115133
	INT-001(B)C1	10/674,803	Intranasal Opioid Components	14 Feb 2007	Pending Publication No. US-2008-0004305
	INT-001(B)CP	11/243,613	Intranasal Opioid Compositions, Delivery Devices and Methods of Using Same	5 Oct 2005	Pending Publication No. US-2006-0083691
	INT-001(B)CPC1	11/674,787	Intranasal Opioid Compositions, Delivery Devices and Methods of Using Same	14 Feb 2007	Pending Publication No. US-2007-0209660
	INT-002C1CP	10/803,521	Intranasal Benodiazepine Compounds	17 Mar 2004	Pending Publication No. US-2004-0176359
	INT-002CPC1	11/457,403	Intranasal Benzodiazepine Compositions	13 Jul 2006	Pending Publication No. US-2007-0071687
	INT-004	11/673,874	Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same	12 Feb 2007	Pending Publication No. US-2007-0212307
	INT-007C1	11/204,611	Programmable Multi-Dose Intranasal Drug Delivery Device	16 Aug 2005	Pending Publication No. US-2006-0021614
	INT-008	11/515,607	Compositions and Methods for Intranasal Delivery of Tricyclic Cannabinoids	5 Sept 2006	Pending Publication No. US-2007-0060639
	INT-010	12/016,724	Methods and Compositions for the Delivery of a Therapeutic Agent	18 Jan 2008	Pending
Date Considered:		Examiner's Name:			

Applicant respectfully requests that the Examiner consider these listed documents and indicate that each was considered by making appropriate notations on this Information

Disclosure Statement. Applicant also brings to the attention of the Examiner that an Office Action was mailed on January 10, 2008 in co-pending U.S. Application Serial No. 11/674,803.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Deposit Account No. 07-1700 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 07-1700, under Order No. INT-001B.

Dated: June 2, 2008

Respectfully submitted,

/Chad E. Davis/
Chad E. Davis
Registration No.: 56,179
GOODWIN PROCTER LLP
Exchange Place
Boston, Massachusetts 02109
(617) 570-1000
Agent for Applicant